The response to levodopa in Parkinson's disease: Imposing pharmacological law and order

Annals of Neurology

Volumn 39, Issue 5, 1996, Pages 561-573

  Nutt, John G ^a,c   Holford, Nicholas H G ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA;

CIRCADIAN RHYTHM; CONCENTRATION RESPONSE; DOPAMINE METABOLISM; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RESPONSE; DYSKINESIA; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

CIRCADIAN RHYTHM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MOTOR ACTIVITY; PARKINSON DISEASE; TIME FACTORS;

EID: 0029883235     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410390504     Document Type: Review

References (98)

1. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981:6:429-453
2. Holford NHG. Physiological alternatives to the effect compartment model. In: D'Argenio DZ, ed. Advanced methods of pharmacokinetic and pharmacodynamic systems analysis. New York: Plenum, 1991:55-59
3. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part I. Ann Neurol 1988;24:366-371
4. Gancher ST, Nutt JG, Woodward WR. Response to brief levodopa infusions in parkinsonian patients with and without motor fluctuations. Neurology 1988;38:712-716
5. Contin M, Riva R, Martinelli P, et al. Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 1990;13:19-28
6. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol 1992;49:1123-1130
7. Contin M, Riva R, Martinelli P, et al. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 1994;44:1287-1292
8. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986;36:739-744
9. Holford N. MK model: a quantitative modeling system for pharmacologists. 5. Cambridge, MA: Biosoft, 1994:1-273
10. Contin M, Riva R, Martinelli P, et al. Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease. Neurology 1993;43:367-371
11. Hughes AJ, Frankel JP, Kempster PA, et al. Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. J Neurol Neurosurg Psychiatry 1994;57:430-434
12. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-378
13. Bravi D, Mouradian MD, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contributions of postsynaptic mechanisms. Ann Neurol 1994;36:27-31
14. Marsden CD, Parkes JD. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1977;1:345-349
15. Yahr MD. Long-term levodopa in Parkinsons disease. Lancet 1977;1:706-707
16. Durso R, Isaac K, Perry L, et al. Age influences magnitude but not duration of response to levodopa. J Neurol Neurosurg Psychiatry 1993;56:65-58
17. Marsden CD. Neurologic management: Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681
18. Sohn YH, Metman LV, Bravi D, et al. Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease. Neurology 1994;44:755-757
19. Klockowski PM, Levy G. Kinetics of drug action in disease states XXI. Relationship between drug infusion rate and dose required to produce a pharmacological effect. J Pharm Sci 1987;76:516-520
20. Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376
21. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable and fluctuating parkinsonian patients. Neurology 1987;37:940-944
22. Bianchine JR, Rivera-Calimlim L, Morgan JP, Dujovne CA. Metabolism and absorption of L-3,4 dihydroxyphenylalanine in patients with Parkinson's disease. Ann NY Acad Sci 1971; 179:126-140
23. Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 1984;310:483-488
24. Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-537
25. Wade DN, Mearrick PT, Birkett DJ, Morris J. Variability of L-dopa absorption in man. Aust NZ J Med 1974;4:138-143
26. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;2:412-415
27. Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause "random" fluctuations of parkinsonian mobility. Neurology 1988;38:419-421
28. Deleu D, Ebinger G, Michotte Y. Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa. Eur J Clin Pharmacol 1991;41:453-458
29. Mouradian MM, Heuser IJE, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23
30. Schuh LA, Bennett JP. Suppression of dyskinesia in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesia but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550
31. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276:374-379
32. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-dopa. N Engl J Med 1969;280:337-345
33. Muenter MD, Tyce GM. L-DOPA therapy of Parkinson's disease: plasma L-DOPA concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239
34. Ogasahara S, Nishikawa Y, Takahashi M, et al. Dopamine metabolism in the central nervous system after discontinuation of L-dopa therapy in patients with Parkinson's disease. J Neurol Sci 1984;66:151-163
35. Kaye JA, Feldman RG. The role of L-DOPA holiday in the long-term management of Parkinson's disease. Clin Neuropharmacol 1986;9:1-13
36. Turjanski N, Fernandez W, Lees AJ. The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1993;56:771-775
37. Nutt JG, Carter JH, Woodward WR. Long duration response to levodopa. Neurology 1995;45:1613-1616
38. Nutt JG, Carter JC, Woodward WR. Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects. Neurology 1994; 44:1617-1622
39. Quattrone A, Zappia M. Oral pulse levodopa therapy in mild Parkinson's disease. Neurology 1993;43:1161-1163
40. Sweet RD, Lee JE, Spiegel HE, McDowell F. Enhanced response to low doses of levodopa after withdrawal from chronic treatment. Neurology 1972;22:520-525
41. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984;107:487-506
42. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988;38:1553-1557
43. Kempster PA, Frankel JP, Stern GM, Lees AJ. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 1990;53:1004-1007
44. Paalzow GHM, Paalzow LK. L-Dopa: how it may exacerbate parkinsonian symptoms. Trends Pharmacol Sci 1986;9:15-19
45. Stromberg U. DOPA effects on motility in mice: potentiation by MK 485 and dexchlorpheniramine. Psychopharmacology 1970;18:58-67
46. Merello M, Lees AJ. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:1024-1026
47. Marconi R, Lefebvre-Caparros D, Bonnet A, et al. Levodopa-induced dyskinesia in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994;9:2-12
48. Luquin MR, Scipioni O, Vaamonde J, et al. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124
49. Markham CH. The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Ther 1971;12(pt 2):340-343
50. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesia in 51 patients with parkinsonism. J Neurol Neurosurg Psychiatry 1971;34:668-673
51. Boyce S, Rupnaik NMJ, Steventon MJ, Iverson SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990;5: 448-458
52. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1992; 41:174-181
53. Harwood G, Hierons R, Fletcher NA, Marsden CD. Lessons from a remarkable family with dopa-responsive dystonia. J Neurol Neurosurg Psychiatry 1994;57:460-463
54. Horstink MWIM, Zijlmans JCM, Pasman JW, et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. J Neurol Neurosurg Psychiatry 1990;53:224-226
55. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989;34:193-196
56. Boyce S, Clarke CE, Luquin R, et al. Induction of chorea and dystonia in parkinsonian primates. Mov Disord 1990;5:3-7
57. Mouradian MM, Heuser IJE, Baronti F, et al. Pathogenesis of dyskinesia in Parkinson's disease. Ann Neurol 1989;25:523-526
58. Dogali M, Fazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995;45:753-761
59. Bernheimer H, Birkmayer W, Hornykiewicz O. Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological, and neurochemical correlations. J Neurol Sci 1973;20:415-455
60. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-880
61. Alexander GM, Schwartzman RJ, Brainard L, et al. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res 1992; 588:261-269
62. Zhang WQ, Tilson HA, Nanry KP, et al. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res 1988;461:335-342
63. Wachtel SR, Abercrombie ED. L-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 1994;63:108-117
64. Castaneda E, Whishaw IQ, Robinson TE. Changes in striatal dopamine neurotransmission assessed with microdialysis following recovery from a bilateral 6-OHDA lesion: variation as a function of lesion size. J Neurosci 1990;10:1847-1854
65. Marsden CD. "On-off" phenomena in Parkinson's disease. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's disease: current progress, problems and management. Amsterdam: Elsevier/North-Holland Biomedical, 1980:241-254
66. Comella CL, Bohmer J, Stebbins GT. Sleep benefit in Parkinson's disease. Neurology 1995;45(suppl 4):A286 (Abstract)
67. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1:292-296
68. Rusk GD, Siemers ER. Diurnal variation in motor ability in Parkinson's disease. Ann Neurol 1993;34:266-267 (Abstract)
69. Stolz G, Aschoff JC, Born J, Aschoff J. VEP, physiological and psychological circadian variations in humans. J Neurol 1988; 235:308-313
70. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-633
71. Frankel JP, Pirtosek Z, Kempster PA, et al. Diurnal differences in response to oral levodopa. J Neurol Neurosurg Psychiatry 1990;53:948-950
72. Contin M, Riva R, Martinelli P, Baruzzi A. Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease. Mov Disord 1992;7: 244-248
73. Gancher ST, Nutt JG. Diurnal responsiveness to apomorphine. Neurology 1987;37:1250-1253
74. Nutt JG, Woodward WR, Carter JH, Trotman T. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989;52:481-487
75. Struck LK, Rodnitzky RL, Dobson JK. Circadian fluctuations of contrast sensitivity in Parkinson's disease. Neurology 1990; 40:467-470
76. Lemmer B, Berger T. Diurnal rhythm in the central dopamine turnover in the rat. Naunyn Schmiedebergs Arch Pharmacol 1978;303:257-261
77. Smith AD, Olson RJ, Justice JB. Quantitative microdialysis of dopamine in the striatum: effect of carcadian variation. J Neurosci Methods 1992;44:33-41
78. Baronti F, Mouradian MM, David TL, et al. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Ann Neurol 1992;32:776-781
79. Gancher ST, Nutt JG, Woodward WR. Time-course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992;52:504-510
80. Grandas F, Gancher ST, Rodriguez M, et al. Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson's disease. Clin Neuropharmacol 1992;15:13-18
81. Rodriguez M, Lera G, Vaamonde J, et al. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease, J Neurol Neurosurg Psychiatry 1994;57:562-566
82. Leenders KL, Palmer AJ, Quinn N, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-860
83. Vingerhoets FJG, Snow BJ, Holden JE, et al. The fluorodopa loss rate constant in normal subjects and Parkinson's disease patients. Neurology 1995;45:A410 (Abstract)
84. Spencer SE, Wooten GF. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation. Neurology 1984;34:1105-1108
85. Kuczenski R, Segal DS. Psychomotor stimulant-induced sensitization: behavior and neurochemical correlates. In: Kalivas PW, Barnes CD, eds. Sensitization in the nervous system. Caldwell, NJ: Telford, 1988:177-205
86. Morelli M, Fenu S, Garau L, Di Chiara G. Time and dose dependence of the 'priming' of the expression of dopamine receptor supersensitivity. Eur J Pharmacol 1989;162:329-335
87. Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547: 152-161
88. Spivak CE. Correlations among Hill parameters reflect models of activating ligand-gated ion channels. Trends Pharmacol Sci 1995;16:39-42
89. 14C]-2-deoxyglucose autoradiographic study. Brain 1991;114:1429-1440
90. LaHoste GJ, Marshall JF. The role of dopamine in the maintenance and breakdown of D1/D2 synergism. Brain Res 1993; 611:108-116
91. Rinne JO, Laihinen A, Lonnberg P, et al. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Brain Res 1991;556:117-122
92. Rinne UK, Sonninen V. Brain catecholamines and their metabolites in parkinsonian patients. Arch Neurol 1973;28:107-110
93. Lloyd KG, Davidson L, Hornykiewicz O. The neurochemistry of Parkinson's disease: effect of L-DOPA therapy. J Pharmacol Exp Ther 1975;195:453-464
94. Cotzias GC, Papavasilious PS, Fehling C, et al. Similarities between neurologic effects of L-DOPA and of apomorphine. N Engl J Med 1970;282:31-33
95. Hefti F, Melamed E, Sahakian BJ, Wurtman RJ. Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacol Biochem Behav 1980;12:185-188
96. Thorns J, Wang J, Takubo H, et al. A 6-hydroxydopamine-induced selective parkinsonism rat model: further biochemical and behavioral characterization. Exp Neurol 1994;126:159-167
97. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res 1990;525:36-44
98. van Horne C, Hoffer BJ, Strömberg I, Gerhardt GA. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxydopamine-lesioned rat striatum. J Pharmacol Exp Ther 1992;263:1285-1292